| International Session（Symposium）1(JSH・JSGE) |
| Thu. November 21st 9:30 - 12:00 Room 11: Portopia Hotel South Wing Topaz |
| Clinical Effects of Pemafibrate on Biochemical Response and Plasma Lipids in Patients with Primary Biliary Cholangitis | |||
| Satoru Joshita1, Takeji Umemura1, Eiji Tanaka1 | |||
| 1Department of Gastroenterology, Shinshu University | |||
|
|||
|
|||
| Background and aims: Fibrate addition to ursodeoxycholic acid (UDCA) therapy has been shown to improve both liver biochemistry and long-term prognosis in PBC patients showing an incomplete biochemical response to UDCA alone. We herein describe the clinical outcome of 7 cases of PBC that received the new selective peroxisome proliferator-activated receptor alpha modulator pemafibrate in combination with UDCA therapy to investigate the clinical effects of pemafibrate on biochemical response and plasma lipids in PBC. Methods: Seven patients with PBC and dyslipidemia who had been followed at our hospital for 11-22 years and commenced pemafibrate addition to UDCA were retrospectively analyzed. Results: Despite 4 of 7 cases being switched from bezafibrate to pemafibrate, alkaline phosphatase (ALP) became significantly decreased (P = 0.031) and gamma-glutamyltransferase tended to decrease (P = 0.063) over the 3 months following pemafibrate addition. Two patients exhibited a greater than 50% reduction in ALP. No remarkable differences were observed for plasma lipid levels, alanine aminotransferase, aspartate aminotransferase, or the liver fibrosis marker Mac-2 binding protein glycosylation isomer between these time points. No adverse drug reactions were recorded. Conclusions: Pemafibrate represents another option for PBC patients displaying an inadequate response to UDCA therapy. |
|||
|
Index Term 1: pemafibrate Index Term 2: primary biliary cholangitis |
|||
| Page Top | |||